Pfizer dashes hope for COVID-19 vaccine information earlier than the election

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, bangs a gavel after ringing the closing bell at the New York Stock Exchange (NYSE) on Thursday afternoon, January 17, 2019 in New York City.

Enlarge / Albert Bourla, chief govt officer of Pfizer pharmaceutical firm, bangs a gavel after ringing the closing bell on the New York Inventory Alternate (NYSE) on Thursday afternoon, January 17, 2019 in New York Metropolis. (credit score: Getty | Drew Angerer)

Pfizer’s chief govt has dashed any lingering hope that we’ll glimpse COVID-19 vaccine information earlier than subsequent week’s election.

The pharmaceutical large has the speediest clinical-trial design among the many frontrunners within the COVID-19 vaccine race. And for weeks, Pfizer CEO Albert Bourla has dangled the chance that his firm would have outcomes by the top of October—an attractive prospect picked up by President Donald Trump, who has pushed for October vaccine information to bolster his re-election bid.

However in a name with buyers Tuesday, Bourla indicated an October launch was practically not possible now. Researchers conducting the over 40,000-person trial haven’t but analyzed preliminary information and, even when the information have been out there tomorrow, an outdoor panel would want not less than every week to investigate any outcomes, Bourla mentioned.

Learn 5 remaining paragraphs | Feedback

Related Posts

Leave a Reply

Your email address will not be published.